Harvard Bioscience (HBIO) EBIT (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of EBIT data on file, last reported at -$1.2 million in Q1 2026.

• On a quarterly basis, EBIT rose 97.64% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$86000.0, a 99.84% increase from a year earlier, with the FY2025 full-year figure at -$48.6 million, down 682.16% from the prior year.
• EBIT for Q1 2026 stood at -$1.2 million, down from $1.7 million in the prior quarter.
• Over the last five years, EBIT for HBIO reached as high as $4.0 million in Q2 2022 and fell as low as -$49.7 million in Q1 2025.
• Historically, EBIT has averaged -$3.6 million across 5 years, with a median of -$819000.0 in 2025.
• Across the five-year window, EBIT slumped 2708.37% in 2022 and jumped 15445.45% in 2025, its largest moves.
• Year by year, EBIT stood at -$457000.0 in 2022, then surged by 161.71% to $282000.0 in 2023, then tumbled by 96.1% to $11000.0 in 2024, then soared by 15445.45% to $1.7 million in 2025, then tumbled by 168.65% to -$1.2 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$1.2 million in Q1 2026, $1.7 million in Q4 2025, and $197000.0 in Q3 2025.